Antibiotic prophylaxis for onabotulinum toxin A injections: systematic review and meta-analysis
- 8 November 2023
- journal article
- review article
- Published by Springer Nature in International Urogynecology Journal
- Vol. 35 (1) , 19-29
Abstract
Introduction and hypothesis To our knowledge, there are no evidence-based recommendations regarding the optimal prophylactic antibiotic regimen for intradetrusor onabotulinum toxin type A (BTX) injections. This systematic review and meta-analysis was aimed at investigating the optimal prophylactic antibiotic regimen to decrease urinary tract infection (UTI) in patients undergoing BTX for overactive bladder syndrome (OAB). Methods A systematic search of MEDLINE, Embase, CINAHL, and Web of Science was conducted from inception through 30 June 2022. All randomized controlled trials and prospective trials with > 20 subjects undergoing BTX injections for OAB in adults that described prophylactic antibiotic regimens were included. Meta-analysis performed to assess UTI rates in patients with idiopathic OAB using the inverse variance method for pooling. Results A total of 27 studies (9 randomized controlled trials, 18 prospective) were included, representing 2,100 patients (69% women) with 19 studies of idiopathic OAB patients only, 6 of neurogenic only, and 2 including both. No studies directly compared antibiotic regimens for the prevention of UTI. Included studies favor the use of antibiotics in patients with idiopathic OAB and favor continuing antibiotics for 2–3 days after the procedure for prevention of UTI. Given the heterogeneity of the data, direct comparisons of antibiotic type or duration could not be performed. Meta-analysis found a 10% UTI rate at 4 weeks and 15% at 12 weeks post-injection. Conclusions Although there are insufficient data to support the use of a specific antibiotic regimen, available studies favor the use of prophylactic antibiotics for 2–3 days in idiopathic OAB patients undergoing BTX injection. Future trials are needed to determine the optimal regimens to prevent UTI in patients undergoing BTX for OAB.Keywords
This publication has 39 references indexed in Scilit:
- Detrusor botulinum toxin A injection significantly decreased urinary tract infection in patients with traumatic spinal cord injurySpinal Cord, 2013
- Anticholinergic Therapy vs. OnabotulinumtoxinA for Urgency Urinary IncontinenceNew England Journal of Medicine, 2012
- The safety and efficacy of botulinum toxin-A in the management of bladder oversensitivity: a randomised double-blind placebo-controlled trialInternational Journal Of Clinical Practice, 2011
- Long-Term Effect on Quality of Life of Repeat Detrusor Injections of Botulinum Neurotoxin-A for Detrusor Overactivity in Patients With Multiple SclerosisJournal of Urology, 2011
- Outcome of a Randomized, Double-Blind, Placebo Controlled Trial of Botulinum A Toxin for Refractory Overactive BladderJournal of Urology, 2009
- What a Patient With Refractory Idiopathic Detrusor Overactivity Should Know About Botulinum Neurotoxin Type A InjectionJournal of Urology, 2009
- Botulinum injections for the treatment of bladder symptoms of multiple sclerosisAnnals of Neurology, 2007
- Efficacy of Botulinum Toxin-A for Treating Idiopathic Detrusor Overactivity: Results From a Single Center, Randomized, Double-Blind, Placebo Controlled TrialJournal of Urology, 2007
- Experience With 100 Cases Treated With Botulinum-A Toxin Injections in the Detrusor Muscle for Idiopathic Overactive Bladder Syndrome Refractory to AnticholinergicsJournal of Urology, 2006
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996